Cellartis AB - A Detailed Market Analysis
Entity Overview and Core Business
The entity originally known as Cellartis AB was a Swedish biotechnology company founded in 2001 as a spin-out from the Sahlgrenska Academy at the University of Gothenburg. Cellartis quickly established itself as a pioneer and key supplier in the nascent field of human stem cell research, concentrating on human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs). The company was acquired by Cellectis SA in 2011, which was then acquired by Takara Bio Inc. in December 2014. Today, the Cellartis name is preserved as a globally recognized Cellartis brand for stem cell-derived products and services, primarily operating out of its state-of-the-art facilities in Gothenburg, Sweden, under the legal entity Takara Bio Europe AB.
Continue…The primary focus of the Cellartis entity is the research, development, manufacture, and distribution of highly functional, mature, human pluripotent stem cell-derived cells and systems. The products are specifically engineered to provide physiologically relevant in vitro models for a variety of applications in the life sciences, addressing the critical needs of drug discovery, toxicology testing, and regenerative medicine research. Cellartis leverages its two decades of experience in stem cell handling, scale-up, and leading expertise in the directed differentiation of pluripotent stem cells into specific, terminally differentiated, and functional cell types.
Key Focus Areas and Applications
The core of the Cellartis offering revolves around providing scalable, consistent, and high-quality human cell models to replace less predictive animal models and variably sourced primary cells.
Drug Discovery and Toxicity Testing (DART)
- Cellartis products are an essential tool for safety pharmacology and toxicology screening, particularly for predicting drug adverse effects which are a major cause of attrition in drug development.
- Cardiotoxicity Testing: The Cellartis hiPS cell-derived cardiomyocytes are a crucial product, as they are spontaneously beating cells that express the expected major cardiac markers and ion channels. These cells exhibit a physiological response to cardiac stimuli and are used extensively for pro-arrhythmia screening and other cardiac safety assays, including those aligned with the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative.
- Drug Metabolism and Hepatotoxicity: The Cellartis Enhanced hiPS-HEP cells (hepatocytes) are marketed as a consistent and inexhaustible alternative to variable human primary hepatocytes. They display robust drug-metabolizing enzyme activity and transporter functions, making them ideal for studying drug-induced liver injury (DILI) and drug metabolism, pharmacokinetics, and pharmacodynamics (ADME/PK/PD).
Disease Modeling and Personalized Medicine
- Cellartis offers a platform for disease modeling by providing functional cells that can harbor genetically determined characteristics, which is key for understanding inter-individual variations in drug response.
- Metabolic Disease Research: The hiPS-HEP cells are used to advance the understanding of liver metabolism-related diseases, such as Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis (NAFLD/NASH) and type 2 diabetes.
- Diabetes Research: The portfolio includes fully differentiated, functional Cellartis hiPS beta cells, which are utilized for drug screening and to model beta-cell function, encouraging breakthroughs in personalized diabetes treatment.
Regenerative Medicine
- The core competence in human pluripotent stem cells and their controlled differentiation forms the technological basis for future applications in cell therapy and regenerative medicine. The ability to culture and differentiate cells using xeno-free, chemically-defined, and GMP-grade media is essential for translational and clinical development projects.
Products and Services Offered
The Cellartis product portfolio is structured to support the entire stem cell workflow, from cell expansion to final differentiation and application.
Pluripotent Stem Cell Lines:
- Human Embryonic Stem Cell (hESC) Lines: Cellartis maintains a collection of proprietary, well-documented hES cell lines (originally over 30), a significant resource for the research community.
- Human Induced Pluripotent Stem Cell (hiPSC) Lines: A broad range of characterized hiPSC lines are available, providing the genetic starting material for disease modeling and differentiation.
Functional Differentiated Cell Products (Ready-to-Use):
- Cellartis Enhanced hiPS-HEP cells: Highly homogeneous, functional hepatocytes, provided in a cryopreserved format.
- Cellartis hiPS cell-derived Cardiomyocytes: Spontaneously beating cardiomyocytes, used for cardiac toxicity and functional assays. Cellartis was a leader in bringing the first human embryonic stem cell-derived cardiomyocytes to the market.
- Cellartis hiPS beta cells: Fully differentiated beta cells for diabetes and glucose-regulation studies.
Culture and Differentiation Systems/Media:
- Cellartis DEF-CS Culture System: A pivotal product, this is a xeno-free (free from human and animal components), chemically-defined medium for the robust, efficient, and reproducible expansion of undifferentiated hiPS cells. A GMP-grade version is also offered to support pre-clinical and clinical-grade applications.
- Cellartis iPS Cell to Hepatocyte Differentiation System: A comprehensive, all-in-one kit that includes optimized media and standardized protocols for researchers to differentiate their own hiPSCs into functional hepatocytes.
- Cellartis Differentiation Media and Kits: This includes individual kits for key steps, such as the Definitive Endoderm Differentiation Kit, as well as other media like RHB-A and NDiff 227 for neuronal and other specific differentiations.
Custom Services:
- The Cellartis brand offers customizable services encompassing cell sourcing, iPS cell generation, differentiation into specialized cell types, and other contract development and manufacturing organization (CDMO) services to support client-specific research programs.
In summary, the Cellartis entity, operating as a key stem cell brand of Takara Bio Europe AB, provides end-to-end solutions that allow researchers to overcome the technical hurdles of stem cell culture. By supplying high-quality pluripotent stem cells, proprietary xeno-free culture systems, and validated functional cells like hepatocytes and cardiomyocytes, Cellartis is an integral part of the global effort to develop more accurate human-based in vitro models for pharmaceutical research and development.
